SYSTM Wealth Solutions LLC Sells 2,799 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

SYSTM Wealth Solutions LLC reduced its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 37.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,679 shares of the company’s stock after selling 2,799 shares during the quarter. SYSTM Wealth Solutions LLC’s holdings in Takeda Pharmaceutical were worth $61,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in TAK. Rise Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $26,000. Principal Securities Inc. acquired a new stake in Takeda Pharmaceutical in the fourth quarter worth $28,000. GAMMA Investing LLC increased its stake in Takeda Pharmaceutical by 50.9% in the first quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after purchasing an additional 966 shares in the last quarter. Headlands Technologies LLC bought a new stake in Takeda Pharmaceutical in the second quarter valued at $59,000. Finally, Blue Trust Inc. raised its holdings in shares of Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after purchasing an additional 2,330 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $14.93 on Friday. The business has a 50-day simple moving average of $14.30 and a 200 day simple moving average of $13.76. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $16.39. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. The firm has a market capitalization of $47.51 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. The firm had revenue of $7.75 billion during the quarter. On average, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.